GMP IPO Watch
UTI - Healthcare Fund
Regular Plan · IDCW · UTI Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.31% | +3.52% | 184 of 255 |
| 1M | +1.80% | +1.97% | 146 of 255 |
| 3M | +0.38% | -3.45% | 30 of 252 |
| 6M | +13.88% | +2.92% | 22 of 251 |
| YTD | +18.70% | +1.21% | 12 of 255 |
| 1Y | +15.42% | +1.11% | 20 of 232 |
| 2Y | +9.07% | +2.39% | 26 of 187 |
| 3Y | +22.96% | +12.36% | 7 of 142 |
| 5Y | +15.56% | +9.81% | 18 of 102 |
| 7Y | +22.33% | +14.27% | 7 of 84 |
| 10Y | +14.45% | +11.68% | 21 of 68 |
| INCEPTION | +12.92% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +3.77% | +46.97% | -33.38% | 64% | 25% |
| 6M | +7.80% | +72.71% | -34.79% | 67% | 27% |
| 1Y | +16.40% | +99.36% | -32.43% | 68% | 29% |
| 2Y | +15.39% | +52.66% | -17.00% | 77% | 34% |
| 3Y | +15.31% | +37.94% | -12.23% | 88% | 39% |
| 5Y | +14.51% | +31.03% | -5.43% | 98% | 43% |
| 7Y | +14.27% | +27.94% | +4.94% | 100% | 45% |
| 10Y | +13.10% | +16.99% | +7.51% | 100% | 45% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity94.13%
- Debt0.00%
- Cash5.87%
- Other0.00%
Market Cap Split
- Large Cap18.21%
- Mid Cap34.69%
- Small Cap41.25%
- Others5.85%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 38.71 | 41.75 |
| P/B | 5.38 | 6.19 |
| Price / Sales | 5.53 | 5.96 |
| Price / Cash Flow | 30.61 | 30.98 |
| Dividend Yield (%) | 0.55 | 0.61 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 7.62% | -0.63% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 6.15% | -0.06% |
| NET CURRENT ASSETS | Net Current Assets | 5.85% | — |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 5.24% | +1.62% |
| Ajanta Pharma | Pharmaceuticals & Biotechnology | 4.81% | +0.07% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 4.06% | +0.36% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 3.70% | +0.41% |
| Apollo Hospitals | Equity | 3.03% | -0.24% |
| Caplin Point Laboratories | Pharmaceuticals & Biotechnology | 3.02% | -0.03% |
| Global Health | Equity | 2.96% | +0.15% |
| Lupin | Pharmaceuticals & Biotechnology | 2.89% | -0.20% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 2.81% | -0.06% |
| Max Healthcare Institute | Equity | 2.80% | -0.30% |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 2.79% | +0.58% |
| Marksans Pharma | Pharmaceuticals & Biotechnology | 2.25% | +0.02% |
View all 46 holdings
| Rainbow Childrens Medicare | Equity | 2.21% | -0.04% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 2.12% | -0.11% |
| Jupiter Life Line Hospital | Equity | 2.09% | -0.08% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 2.07% | -0.03% |
| Fortis Healthcare | Equity | 2.02% | -0.34% |
| Procter & Gamble Health | Pharmaceuticals & Biotechnology | 1.95% | -0.05% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 1.80% | -0.82% |
| Aster DM Quality Care | Equity | 1.76% | -0.13% |
| Dr. Lal Path Labs | Equity | 1.67% | +0.06% |
| Biocon | Pharmaceuticals & Biotechnology | 1.62% | +0.20% |
| Metropolis Healthcare | Equity | 1.47% | -0.09% |
| Windlas Biotech | Pharmaceuticals & Biotechnology | 1.42% | +0.14% |
| Cipla | Pharmaceuticals & Biotechnology | 1.41% | -0.05% |
| Blue Jet Healthcare | Pharmaceuticals & Biotechnology | 1.41% | +0.42% |
| Alembic Pharmaceuticals | Pharmaceuticals & Biotechnology | 1.40% | +0.24% |
| Viyash Scientific | Pharmaceuticals & Biotechnology | 1.39% | -0.15% |
| Vijaya Diagnostic Centre | Equity | 1.33% | -0.06% |
| Sudeep Pharma | Chemicals & Petrochemicals | 1.28% | -0.14% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 1.26% | -0.53% |
| Eris Lifesciences | Pharmaceuticals & Biotechnology | 1.13% | -0.08% |
| Laxmi Dental | Equity | 1.08% | +0.10% |
| Manipal Health Enterprises | Equity | 1.05% | -0.07% |
| Aarti Pharma Labs | Pharmaceuticals & Biotechnology | 1.00% | +0.12% |
| Pfizer | Pharmaceuticals & Biotechnology | 0.93% | -0.18% |
| Orchid Pharma | Pharmaceuticals & Biotechnology | 0.71% | +0.03% |
| Sanofi Consumer Healthcare | Pharmaceuticals & Biotechnology | 0.67% | -0.02% |
| Jubilant Pharmova | Pharmaceuticals & Biotechnology | 0.65% | +0.10% |
| Indegene | Equity | 0.50% | — |
| Syngene International | Equity | 0.42% | -0.03% |
| Emcure Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.20% | -0.69% |
| CLEARING CORPORATION OF INDIA LTD. STD - MARGIN | Net Current Assets | 0.02% | — |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.33 | 16.32 | Low Volatility |
| 3Y | 13.62 | 16.10 | Low Volatility |
| 5Y | 13.28 | 15.67 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.54 | -0.32 | Above Average |
| 3Y | 1.02 | -0.45 | Above Average |
| 5Y | 0.63 | 0.29 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.73% (published 2026-10-28).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.75 | 0.19 | Above Average |
| 3Y | 2.35 | 1.14 | Above Average |
| 5Y | 1.70 | 0.96 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.97 | 0.96 | Poor Risk Adjusted Returns |
| 3Y | 0.97 | 0.96 | Poor Risk Adjusted Returns |
| 5Y | 0.96 | 0.95 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From UTI Asset Mgmt. Co. Ltd.
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
UTI Silver Exchange Traded Fund
Direct Plan · Growth
|
+26.53% | +35.98% | — | +27.77% |
|
UTI Silver ETF Fund of Fund
Direct Plan · Growth
|
+25.46% | +35.71% | — | +25.36% |
|
UTI - Gold Exchange Traded Fund
Direct Plan · Growth
|
+16.90% | +31.24% | +23.48% | +13.76% |
|
UTI Gold ETF Fund of Fund
Direct Plan · Growth
|
+16.56% | +31.28% | — | +28.21% |
|
UTI - Arbitrage Fund
Direct Plan · Growth
|
+6.53% | +7.28% | +6.75% | +6.76% |
|
UTI - Liquid Fund
Direct Plan · Half-Yearly IDCW
|
+6.52% | +6.92% | +6.45% | +4.98% |
|
UTI Ultra Short Term Fund
Direct Plan · Annual IDCW
|
+6.48% | +7.25% | +5.93% | +3.95% |
|
UTI - Money Market Fund
Direct Plan · Half-Yearly IDCW
|
+6.37% | +7.30% | +6.78% | +6.45% |
|
UTI Ultra Short to Short Term Fund
Direct Plan · Half Yearly IDCW
|
+5.80% | +7.14% | +5.97% | +3.55% |
|
UTI - Credit Risk Fund.
Direct Plan · Half yearly IDCW
|
+5.79% | +7.63% | +6.88% | +2.06% |
About This Scheme
Investment Objective
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Stated Asset Allocation
Equity and equity related instruments of entities related to the healthcare services sector: 80% - 100% Money Market Instruments and other instruments permissible under residual portion: 0% - 20%
Exit Load
1.00% if redeemed before 30 days from the date of allotment. Nil if redeemed on or after 30 days from the date of allotment
Fund Managers
Mr. Kamal Gada FM 1,Not Applicable FM 2,Not Applicable FM 3
Primary FM 1,Not Applicable FM 2,Not Applicable FM 3
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.